Notable 52-Week Highs and Lows 1/2: (BCLI) (KITE) (DGX) High; (HNR) (SWN) Low - InvestingChannel

November 18, 2024

Notable 52-Week Highs and Lows 1/2: (BCLI) (KITE) (DGX) High; (HNR) (SWN) Low

by Street Insider079

52-Week High:

  • Brainstorm Cell Therapeutics (Nasdaq: BCLI) $8.47. Brainstorm Cell Therapeutics gaining in anticipation of the NurOwn phase 2a in ALS. CEO Tony Fiorino noted that there weren’t any partnership deals in the works to explain the recent stock surge. For more color, click here.

  • Kite Pharma (Nasdaq: KITE) $60.99. Credit Suisse maintained an Outperform rating on Kite Pharma, but raised its price target from $34 up to $71.00. Analyst Jason Kantor expects continued excitement for CAR-T technologies. Click here for more color.

  • Quest Diagnostics (NYSE: DGX) $69.58. Quest moving